Scarica l'app Stockscreener
0.3245
7.49%
0.0226
Dopo l'orario di chiusura:
.32
-0.0045
-1.39%
Precedente Chiudi:
$0.3019
Aprire:
$0.2974
Volume 24 ore:
2.35M
Relative Volume:
4.04
Capitalizzazione di mercato:
$9.35M
Reddito:
-
Utile/perdita netta:
$-29.77M
Rapporto P/E:
-0.0212
EPS:
-15.2954
Flusso di cassa netto:
$-24.23M
1 W Prestazione:
+6.92%
1M Prestazione:
-62.70%
6M Prestazione:
-80.91%
1 anno Prestazione:
-90.59%
Intervallo 1D:
$0.2911
$0.33
Intervallo di 1 settimana:
$0.28
$0.42
Portata 52W:
$0.25
$4.707
Moleculin Biotech Inc Stock (MBRX) Company Profile
Nome
Moleculin Biotech Inc
Settore
Industria
Telefono
713-300-5160
Indirizzo
5300 MEMORIAL DRIVE, HOUSTON, TX
Confronta MBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.3245 | 9.35M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-09 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-12 | Downgrade | Maxim Group | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
Moleculin Biotech Inc Borsa (MBRX) Ultime notizie
Moleculin Biotech (MBRX) Rating Reiterated with $4.00 Price Target | MBRX Stock News - GuruFocus
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan - GuruFocus
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML - GlobeNewswire
Moleculin Participates in Virtual Investor “What This Means” Seg - GuruFocus
Moleculin Biotech’s Annamycin Pediatric Study Approved by FDA - TipRanks
Moleculin Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Moleculin Biotech (MBRX) Advances Pediatric Cancer Treatment Study | MBRX Stock News - GuruFocus
Moleculin Receives Critical FDA Support for Children's Leukemia Treatment Development - Stock Titan
Moleculin Biotech, Inc. Advances Annamycin for Pediatric Cancer Treatment as FDA Approves Inclusion of Younger Patients in Clinical Study - Nasdaq
FDA agrees to Moleculin’s pediatric study plan for cancer drug - Investing.com
Moleculin Biotech announces ‘What This Means’ virtual investor segment - Yahoo Finance
What is HC Wainwright’s Estimate for MBRX Q2 Earnings? - Defense World
Moleculin Biotech (MBRX) Reports Positive Results from Annamycin Trial | MBRX Stock News - GuruFocus
Moleculin Participates in Virtual Investor “What This Means” Segment | MBRX Stock News - GuruFocus
Moleculin Biotech, Inc. Reports Positive Topline Results from Phase 1B/2 Trial of Annamycin for Soft Tissue Sarcoma Lung Metastases - Nasdaq
Research Analysts Offer Predictions for MBRX Q4 Earnings - Defense World
Moleculin Biotech (NASDAQ:MBRX) Stock Rating Upgraded by HC Wainwright - Defense World
Moleculin Biotech (MBRX) Receives "Buy" Rating and $4.00 Price Target | MBRX Stock News - GuruFocus
Moleculin Biotech Reports Positive Annamycin Trial Results - MSN
Moleculin Biotech (MBRX) Receives Buy Rating and $4 Price Target | MBRX Stock News - GuruFocus
Moleculin Biotech Stock (MBRX) Dives 10% on Clinical Trial Results - The Globe and Mail
Moleculin Releases On-Demand KOL Webcast to Discuss Data - GlobeNewswire
Transcript : Moleculin Biotech, Inc.Pre Recorded Shareholder/Analyst Call - MarketScreener
Moleculin Biotech, Inc. Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - MarketScreener
Moleculin Biotech Hosts Key Opinion Leaders Event - TipRanks
Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Moleculin Biotech (MBRX) Presents Final Data from Annamycin Clin - GuruFocus
Leading Oncologists Review Breakthrough Data from Moleculin's Sarcoma Lung Metastases Trial - Stock Titan
Moleculin announces efficacy results from trial of Annamycin for STS lung mets - Yahoo Finance
Moleculin Reports Positive Topline Efficacy Results from U.S. Ph - GuruFocus
Moleculin Biotech Shares Slump After Phase 1b/2 Trial of Annamycin Fails to Show Complete Responses - MarketScreener
Moleculin Biotech (MBRX) Reports Promising Phase 1B/2 Trial Resu - GuruFocus
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) | MBRX Stock News - GuruFocus
Moleculin Biotech Reports Promising Efficacy Results for Annamycin in Phase 1B/2 Trial for Soft Tissue Sarcoma Lung Metastases - Nasdaq
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - GlobeNewswire
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - GlobeNewswire Inc.
Breakthrough: Moleculin's Cancer Drug Achieves 59.4% Clinical Benefit Rate in Late-Stage Trial - Stock Titan
Roth Capital Partners Manages New Developments for Moleculin Biotech (MBRX) | MBRX Stock News - GuruFocus
Roth Capital Partners Manages New Developments for Moleculin Bio - GuruFocus
Moleculin receives Nasdaq non-compliance notice By Investing.com - Investing.com South Africa
Moleculin Biotech Faces Nasdaq Non-Compliance Notice - TipRanks
Moleculin receives Nasdaq non-compliance notice - Investing.com
Moleculin signals first 45-patient unblinding for Phase 3 AML trial by end of 2025 as key regulatory milestones achieved - MSN
Q2 EPS Forecast for Moleculin Biotech Increased by Analyst - Defense World
Moleculin Biotech reaches agreement to amend investor warrants - MSN
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Moleculin Announces First European Approval for Phase 3 AML Trial - MSN
Moleculin Biotech’s Earnings Call: Trials and Triumphs - TipRanks
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: S - GuruFocus
Moleculin Biotech Inc Azioni (MBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moleculin Biotech Inc Azioni (MBRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):